Skip to search formSkip to main contentSkip to account menu

CDB 2914

Known as: CDB-2914 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ulipristalulipristal acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.
Highly Cited
2008
Highly Cited
2008
CDB-2914 for Uterine Leiomyomata Treatment: A Randomized Controlled Trial
OBJECTIVE: To evaluate whether 3-month administration of CDB-2914, a selective progesterone receptor modulator, reduces leiomyoma… 
Review
2008
Review
2008
Interventions for emergency contraception.
BACKGROUND Emergency contraception is using a drug or copper intrauterine device (Cu-IUD) to prevent pregnancy shortly after… 
Highly Cited
2008
Highly Cited
2008
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells.
Effects of progesterone receptor modulator CDB-2914 on the expression of the extracellular matrix (ECM) components were examined… 
Highly Cited
2006
Highly Cited
2006
Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine…
BACKGROUND This study was conducted to evaluate the effects of graded concentrations (10(-8), 10(-7) and 10(-6) M) of… 
Highly Cited
2006
Highly Cited
2006
Inhibition of Proliferation of Endometrial Stromal Cells by Trichostatin A, RU486, CDB-2914, N-Acetylcysteine, and ICI 182780
Background: All current major medications in treating endometriosis are effective in treating pain, most likely through… 
Highly Cited
2005
Highly Cited
2005
Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase…
The present study was conducted to evaluate the effects of the progesterone receptor modulator CDB-2914 on proliferative activity… 
2003
2003
Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women.
BACKGROUND Progesterone receptor modulators have potential therapeutic use in progesterone-dependent conditions such as… 
Highly Cited
2000
Highly Cited
2000
A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women.
Previous studies in women have shown that the antiprogestin mifepristone delays or inhibits folliculogenesis. The purpose of this… 
Highly Cited
2000
Highly Cited
2000
CDB-2914: anti-progestational/anti-glucocorticoid profile and post-coital anti-fertility activity in rats and rabbits.
Our goal was to determine the endocrine and post-coital anti-fertility activity of CDB-2914. Concurrent administration of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License